Cargando…
Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity
SARS-CoV-2 represents an unprecedented public health challenge. While the majority of SARS-CoV-2-infected individuals with mild-to-moderate COVID-19 resolve their infection with few complications, some individuals experience prolonged symptoms lasting for weeks after initial diagnosis. Persistent vi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155927/ https://www.ncbi.nlm.nih.gov/pubmed/34063463 http://dx.doi.org/10.3390/v13050916 |
_version_ | 1783699317903589376 |
---|---|
author | Fang, Hengsheng Wegman, Adam D. Ripich, Kianna Friberg, Heather Currier, Jeffrey R. Thomas, Stephen J. Endy, Timothy P. Waickman, Adam T. |
author_facet | Fang, Hengsheng Wegman, Adam D. Ripich, Kianna Friberg, Heather Currier, Jeffrey R. Thomas, Stephen J. Endy, Timothy P. Waickman, Adam T. |
author_sort | Fang, Hengsheng |
collection | PubMed |
description | SARS-CoV-2 represents an unprecedented public health challenge. While the majority of SARS-CoV-2-infected individuals with mild-to-moderate COVID-19 resolve their infection with few complications, some individuals experience prolonged symptoms lasting for weeks after initial diagnosis. Persistent viral infections are commonly accompanied by immunologic dysregulation, but it is unclear if persistent COVID-19 impacts the development of virus-specific cellular immunity. To this end, we analyzed SARS-CoV-2-specific cellular immunity in convalescent COVID-19 patients who experienced eight days or fewer of COVID-19 symptoms or symptoms persisting for 18 days or more. We observed that persistent COVID-19 symptoms were not associated with the development of an overtly dysregulated cellular immune response. Furthermore, we observed that reactivity against the N protein from SARS-CoV-2 correlates with the amount of reactivity against the seasonal human coronaviruses 229E and NL63. These results provide insight into the processes that regulate the development of cellular immunity against SARS-CoV-2 and related human coronaviruses. |
format | Online Article Text |
id | pubmed-8155927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81559272021-05-28 Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity Fang, Hengsheng Wegman, Adam D. Ripich, Kianna Friberg, Heather Currier, Jeffrey R. Thomas, Stephen J. Endy, Timothy P. Waickman, Adam T. Viruses Article SARS-CoV-2 represents an unprecedented public health challenge. While the majority of SARS-CoV-2-infected individuals with mild-to-moderate COVID-19 resolve their infection with few complications, some individuals experience prolonged symptoms lasting for weeks after initial diagnosis. Persistent viral infections are commonly accompanied by immunologic dysregulation, but it is unclear if persistent COVID-19 impacts the development of virus-specific cellular immunity. To this end, we analyzed SARS-CoV-2-specific cellular immunity in convalescent COVID-19 patients who experienced eight days or fewer of COVID-19 symptoms or symptoms persisting for 18 days or more. We observed that persistent COVID-19 symptoms were not associated with the development of an overtly dysregulated cellular immune response. Furthermore, we observed that reactivity against the N protein from SARS-CoV-2 correlates with the amount of reactivity against the seasonal human coronaviruses 229E and NL63. These results provide insight into the processes that regulate the development of cellular immunity against SARS-CoV-2 and related human coronaviruses. MDPI 2021-05-15 /pmc/articles/PMC8155927/ /pubmed/34063463 http://dx.doi.org/10.3390/v13050916 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fang, Hengsheng Wegman, Adam D. Ripich, Kianna Friberg, Heather Currier, Jeffrey R. Thomas, Stephen J. Endy, Timothy P. Waickman, Adam T. Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity |
title | Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity |
title_full | Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity |
title_fullStr | Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity |
title_full_unstemmed | Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity |
title_short | Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity |
title_sort | persistent covid-19 symptoms minimally impact the development of sars-cov-2-specific t cell immunity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155927/ https://www.ncbi.nlm.nih.gov/pubmed/34063463 http://dx.doi.org/10.3390/v13050916 |
work_keys_str_mv | AT fanghengsheng persistentcovid19symptomsminimallyimpactthedevelopmentofsarscov2specifictcellimmunity AT wegmanadamd persistentcovid19symptomsminimallyimpactthedevelopmentofsarscov2specifictcellimmunity AT ripichkianna persistentcovid19symptomsminimallyimpactthedevelopmentofsarscov2specifictcellimmunity AT fribergheather persistentcovid19symptomsminimallyimpactthedevelopmentofsarscov2specifictcellimmunity AT currierjeffreyr persistentcovid19symptomsminimallyimpactthedevelopmentofsarscov2specifictcellimmunity AT thomasstephenj persistentcovid19symptomsminimallyimpactthedevelopmentofsarscov2specifictcellimmunity AT endytimothyp persistentcovid19symptomsminimallyimpactthedevelopmentofsarscov2specifictcellimmunity AT waickmanadamt persistentcovid19symptomsminimallyimpactthedevelopmentofsarscov2specifictcellimmunity |